European Journal of Cancer
Volume 38 , Pages S1-S5 , December 2002

ZD0473 pharmacokinetics in Japanese patients: a Phase I dose-escalation study

References 

  1. O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs. 2000;59(Suppl. 4):19–27
  2. Kelland LR, Barnard CDJ. AMD473. Drugs of the Future. 1998;23:1062–1065
  3. Kelland L, Judson I, Koehler M, Stephens T, Roberts D. Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro [2-methylpyridine] platinum [II]). Lung Cancer. 2000;29(Suppl. 1):70; (Abstr 227)
  4. Schiller J, Bonomi P, Modiano M, Cornett P, Kohler M. Activity of ZD0473 in small-cell lung cancer: an update in patients relapsing after one prior chemotherapy regimen. Eur J Cancer. 2001;37(Suppl. 6):S62; (Abstr 219)
  5. Tyrrell C, Bullard S, Barber J, Graham J. Open-label Phase II study of ZD0473 in patients with metastatic hormone-refractory prostate cancer. Eur Urol. 2002;1(Suppl. 1):158; (Abstr 622)
  6. Vandenberg TA, Gelmon KA, Panasci L, et al.  A Phase II trial of ZD0473 in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study (NCIC CTG-IND 129). Eur J Cancer. 2001;37(Suppl. 6):S194; (708)
  7. Stevenson JP, Blair IA, Redlinger M, et al.  Pharmacokinetic (PK)/pharmacodynamic (PD) trial of the novel platinum compound ZD0473 administered as an iv infusion every 21 days. Eur J Cancer. 2001;37(Suppl. 6):S72; (Abstr 255)
  8. Oe T, Tian Y, O'Dwyer PJ, et al.  A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro-(2-methylpyridine)platinum(II) in human plasma ultrafiltrate. Anal Chem. 2002;74:591–599
  9. Trigo JM, Beale P, Judson IR, et al.  Phase I and pharmacokinetic (PK) study of cis-amminedichloro(2-methylpyridine)platinum (II) (ZD0473), a novel sterically hindered platinum complex, in patients with metastatic hormone-refractory prostate cancer. In: Proc Am Soc Clin Oncol. 18:1999;p. 169; (Abstr 648)
  10. Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet. 1997;33:161–183
  11. Oe T, Tian Y, O'Dwyer PJ, et al. Analysis of the platinum drug cis-amminedichloro(2-methylpyridine)platinum(II) in human urine by liquid chromatography/tandem mass spectrometry. J Chromatography (in press).
  12. Treat J, Huang C, Damjanov N, et al.  ZD0473 phase II monotherapy trial in second-line non-small-cell lung cancer. Eur J Cancer. 2001;37(Suppl. 6):S59–S60 (Abstr 209)
  13. Vermorken JB, van der Vijgh WJ, Klein I, et al.  Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep. 1984;68:505–513
  14. Wagstaff AJ, Ward A, Benfield P, Heel RC. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs. 1989;37:162–190

PII: S0959-8049(02)80012-0

European Journal of Cancer
Volume 38 , Pages S1-S5 , December 2002

Article Tools